These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33441174)

  • 1. Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
    Riedlinger GM; Joshi S; Hirshfield KM; Barnard N; Ganesan S
    Breast Cancer Res; 2021 Jan; 23(1):7. PubMed ID: 33441174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Frequency of
    Rosa-Rosa JM; Caniego-Casas T; Leskela S; Cristobal E; González-Martínez S; Moreno-Moreno E; López-Miranda E; Holgado E; Pérez-Mies B; Garrido P; Palacios J
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30641862
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.
    Shamir ER; Chen YY; Krings G
    Mod Pathol; 2020 Jun; 33(6):1078-1091. PubMed ID: 31907376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
    Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
    Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: an experience in our institution and review of the literature.
    Jacobs M; Fan F; Tawfik O
    Ann Diagn Pathol; 2012 Jun; 16(3):185-9. PubMed ID: 22197540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma.
    Haque W; Arms A; Verma V; Hatch S; Brian Butler E; Teh BS
    Breast; 2019 Feb; 43():67-73. PubMed ID: 30496936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
    Uchida S; Kojima T; Sugino T
    Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas.
    Simpson PT; Reis-Filho JS; Lambros MB; Jones C; Steele D; Mackay A; Iravani M; Fenwick K; Dexter T; Jones A; Reid L; Da Silva L; Shin SJ; Hardisson D; Ashworth A; Schmitt FC; Palacios J; Lakhani SR
    J Pathol; 2008 Jul; 215(3):231-44. PubMed ID: 18473330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome in pleomorphic lobular carcinoma: a case-control study with comparison to classic invasive lobular carcinoma.
    Narendra S; Jenkins SM; Khoor A; Nassar A
    Ann Diagn Pathol; 2015 Apr; 19(2):64-9. PubMed ID: 25682191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
    Lien HC; Chen YL; Juang YL; Jeng YM
    Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
    Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
    Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive Pleomorphic Lobular Histology Is an Adverse Prognostic Factor on Survival in Patients with Breast Cancer.
    Sahin S; Karatas F; Erdem GU; Hacioglu B; Altundag K
    Am Surg; 2017 Apr; 83(4):359-364. PubMed ID: 28424130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
    Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
    Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
    Davis AA; Gerratana L; Clifton K; Medford AJ; Velimirovic M; Hensing WL; Bucheit L; Shah AN; D'Amico P; Reduzzi C; Zhang Q; Dai CS; Denault EN; Bagegni NA; Opyrchal M; Ademuyiwa FO; Bose R; Gradishar WJ; Behdad A; Ma CX; Bardia A; Cristofanilli M
    EBioMedicine; 2022 Dec; 86():104316. PubMed ID: 36332363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
    Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
    Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
    McCart Reed AE; Kalinowski L; Simpson PT; Lakhani SR
    Breast Cancer Res; 2021 Jan; 23(1):6. PubMed ID: 33413533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.